![Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - ScienceDirect Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S147751311930436X-fx1.jpg)
Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - ScienceDirect
![Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) - ScienceDirect Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S030228381830352X-gr2.jpg)
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) - ScienceDirect
![Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1477513122003795-gr2.jpg)
Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect
![Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study | Scientific Reports Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-23795-5/MediaObjects/41598_2022_23795_Fig1_HTML.png)